Alimentary Pharmacology & Therapeutics

Papers
(The H4-Index of Alimentary Pharmacology & Therapeutics is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Editorial: Endomysial Antibodies for a No‐Biopsy Diagnosis of Coeliac Disease—The Jury Is Still out. Authors' Reply191
Issue Information141
AP&T: Editors' Declarations of Interest129
Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification118
Issue Information115
108
Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC101
Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease86
Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice—Authors' Reply86
Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease80
Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply79
Systematic Review: Variability in Definitions of Fibrostenosis in Eosinophilic Oesophagitis77
Cost‐effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease71
69
Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Rep68
Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis64
Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis61
Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: a propensity score matching and inverse probability o59
Prevalence and clinical characteristics of patients with metabolic dysfunction‐associated fatty liver disease with hepatitis C virus infection—a population‐based study57
Clinical Trial: Effect of Abdominal Vibration Combined With Walking Exercise Programme on Bowel Preparation in Older Patients With Constipation57
First in human randomised trial of J2H‐1702: A novel 11β‐hydroxysteroid dehydrogenase type 1 inhibitor for non‐alcoholic steatohepatitis treatment56
Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply55
Letter: time to consider Pneumocystis jirovecii pneumonia prophylaxis in treatment of autoimmune hepatitis55
Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease55
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis54
Issue Information52
52
Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply51
Letter: Allostatic load—A potential key in the development of inflammatory bowel disease51
Letter: Elderly onset inflammatory bowel disease—Treat to target approach is still warranted51
Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC51
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B50
Editorial: tradipitant has promise for treating gastroparesis but leaves gastric function alone—authors’ reply50
Editorial: rectal hyposensitivity in patients with hypermobile Ehlers‐Danlos syndrome and constipation—authors' reply49
Editorial: ustekinumab during pregnancy ‐ reassuring but still not enough48
Editorial: Plants against animals48
Letter: ductular reaction is a risk factor for prognosis of chronic hepatitis B complicated with non‐alcoholic fatty liver disease48
Letter: Ozanimod and latent tuberculosis47
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet? Authors' reply45
Editorial: concurrence of coeliac disease with inflammatory bowel disease – is big data the final arbiter? Authors' reply44
Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?43
Letter: practical considerations for nonselective beta‐blocker therapy in portal hypertension43
0.13831996917725